Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 5/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | GRK6 | P43250 | 1/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | MITF | O75030 | 1/20 | 0.40 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.40 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.40 |
| ▸ | GRK5 | P34947 | 1/20 | 0.40 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13225994 | 0.81 | LMNA (0.47) | LMNATDP1ALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL926356 | 0.81 | LMNA (0.56) | LMNAALDH1A1HTTSMN1; SMN2NPC1 | |
| SCHEMBL1531360 | 0.81 | KDM4E (0.49) | LMNATDP1ALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL16014666 | 0.78 | LMNA (0.60) | LMNAALDH1A1HTTSMN1; SMN2L3MBTL1 | |
| SCHEMBL4005594 | 0.78 | LMNA (0.47) | LMNATDP1ALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL13225993 | 0.77 | LMNA (0.44) | LMNAALDH1A1HTTSMN1; SMN2KMT2A | |
| SCHEMBL1167021 | 0.76 | HTR2A (0.51) | LMNATDP1ALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL1674067 | 0.74 | PTGS2 (0.57) | LMNAALDH1A1HTTSMN1; SMN2PTGS2 | |
| SCHEMBL15507848 | 0.74 | ALDH1A1 (0.49) | LMNATDP1CYP2C19ALDH1A1CYP1A2 | |
| SCHEMBL14401081 | 0.73 | TDP1 (0.50) | LMNATDP1CYP2C19ALDH1A1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8618115-B2 | Substituted thieno[3,2-d]pyrimidinones as MCHR1 antagonists and methods for using them | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-12-31 | — | — | US | disclosed |
| EP-1948665-B1 | THIENOPYRIMIDINONE DERIVATIVES AS MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2013-02-27 | — | — | EP | disclosed |
| EP-1948665-B1 | THIENOPYRIMIDINONE DERIVATIVES AS MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2013-02-27 | — | — | EP | disclosed |
| EP-2298776-A1 | Thienopyrimidinone derivatives as melanin concentrating hormone receptor-1 antagonists | Bristol-Myers Squibb Company (US) | 2011-03-23 | — | — | EP | disclosed |
| EP-1948665-A2 | THIENOPYRIMIDINONE DERIVATIVES AS MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS | Bristol-Myers Squibb Company (US) | 2008-07-30 | — | — | EP | disclosed |
| WO-2007050726-A2 | THIENOPYRIMIDINONE DERIVATIVES AS MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-05-03 | — | — | WO | disclosed |
| US-20070093509-A1 | Non-basic melanin concentrating hormone receptor-1 antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2007-04-26 | — | — | US | disclosed |
| US-20070093509-A1 | Non-basic melanin concentrating hormone receptor-1 antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2007-04-26 | — | — | US | disclosed |
| US-20070093509-A1 | Non-basic melanin concentrating hormone receptor-1 antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2007-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093509-A1 | Non-basic melanin concentrating hormone receptor-1 antagonists | MCHR1, MCHR2, MC1R | LMNA 3409/4885TDP1 2046/4885CYP2C19 566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.